REGENXBIO Inc.
RGNX
$6.72
$0.172.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 21.21M | 24.20M | 22.30M | 15.62M | 22.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 21.21M | 24.20M | 22.30M | 15.62M | 22.21M |
| Cost of Revenue | -151.82M | 66.82M | 15.28M | 59.13M | -165.35M |
| Gross Profit | 173.04M | -42.62M | 7.02M | -43.51M | 187.56M |
| SG&A Expenses | 15.05M | 19.42M | 18.86M | 18.29M | 18.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 833.00K | 37.00K | 29.00K | -34.00K | 118.00K |
| Total Operating Expenses | 72.58M | 86.28M | 78.33M | 77.38M | 82.42M |
| Operating Income | -51.37M | -62.08M | -56.04M | -61.76M | -60.20M |
| Income Before Tax | -51.19M | -59.60M | -52.99M | -63.33M | -63.04M |
| Income Tax Expenses | -- | -- | -- | -- | -152.00K |
| Earnings from Continuing Operations | -51.19M | -59.60M | -52.99M | -63.33M | -62.89M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.19M | -59.60M | -52.99M | -63.33M | -62.89M |
| EBIT | -51.37M | -62.08M | -56.04M | -61.76M | -60.20M |
| EBITDA | -47.35M | -58.12M | -51.99M | -57.58M | -55.87M |
| EPS Basic | -1.01 | -1.17 | -1.05 | -1.38 | -1.43 |
| Normalized Basic EPS | -0.63 | -0.73 | -0.65 | -0.84 | -0.84 |
| EPS Diluted | -1.01 | -1.17 | -1.05 | -1.38 | -1.43 |
| Normalized Diluted EPS | -0.63 | -0.73 | -0.65 | -0.84 | -0.84 |
| Average Basic Shares Outstanding | 50.87M | 50.80M | 50.60M | 45.73M | 44.00M |
| Average Diluted Shares Outstanding | 50.87M | 50.80M | 50.60M | 45.73M | 44.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
